Skip to main content
. 2022 Sep 1;6(4):451–464. doi: 10.7150/ntno.75045

Figure 5.

Figure 5

PLAD increased antigen cross presenting dendritic cell infiltration and NK cell activation in tumors. (A-B) Antigen cross presenting dendritic cells (DC1) and conventional dendritic cells (DC2) were gated from the CD11c+ population in Figure 3A. PLAD increased tumor infiltration of DC1, while DC2 infiltration was not affected by any treatment. (C) Gating strategy for NK cells. (D) Although NK cell infiltration in the tumor microenvironment was not affected, (E) PLD and PLAD increased the proportion of activated NK cells. Representative FACS plots are shown. Data are mean with SEM, n=9 for PLAD, PLD and F-Dox, n=5 for vehicle; ANOVA with Tukey's test; *p<0.05, **p<0.01, and ****p<0.0001. F-Dox: free doxorubicin, PLD: pegylated liposomal doxorubicin, PLAD: pegylated liposomal alendronate doxorubicin, DC: dendritic cells, NK: natural killer cells.